CINCINNATI--(BUSINESS WIRE)--Dec. 2, 2008--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today
announced it has filed a shelf registration statement on Form S-3 with
the US Securities and Exchange Commission. This registration statement
replaces the Company's existing shelf registration statement originally
filed in September 2003 which was scheduled to expire on December 1,
2008. This unlimited shelf registration includes common stock, preferred
stock, debt and other types of securities and automatically became
effective upon filing.
Meridian may publicly offer these securities from time to time at prices
and on terms to be determined at the time of the offering. The specific
terms of a future offering, if any, will be provided in a supplemental
prospectus relating to any such offering. The Company will use the
proceeds from any offerings under the registration statement for a
variety of purposes including repayment or refinancing of indebtedness,
working capital, capital expenditures, acquisitions, or other business
opportunities and general corporate purposes.
The shelf registration will provide flexibility for the possible sale of
securities when market conditions are attractive. Meridian has no
immediate plans to draw upon the registration.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state in which such an offer, solicitation, or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state.
A copy of the prospectus included in the registration statement may be
obtained at the SEC's website at www.sec.gov,
and on the Company's website at www.meridianbioscience.com.
In addition, Meridian will file a prospectus supplement with the SEC in
connection with any future offering under the shelf registration
Meridian is a fully integrated life science company that manufactures,
markets and distributes a broad range of innovative diagnostic test
kits, purified reagents and related products and offers
biopharmaceutical enabling technologies. Utilizing a variety of methods,
these products and diagnostic tests provide accuracy, simplicity and
speed in the early diagnosis and treatment of common medical conditions,
such as gastrointestinal, viral and respiratory infections. Meridian's
diagnostic products are used outside of the human body and require
little or no special equipment. The Company's products are designed to
enhance patient well-being while reducing the total outcome costs of
healthcare. Meridian has strong market positions in the areas of
gastrointestinal and upper respiratory infections, serology,
parasitology and fungal disease diagnosis. In addition, Meridian is a
supplier of rare reagents, specialty biologicals and related
technologies used by biopharmaceutical companies engaged in research for
new drugs and vaccines. The Company markets its products and
technologies to hospitals, reference laboratories, research centers,
veterinary testing centers, physician offices, diagnostics manufacturers
and biotech companies in more than 60 countries around the world. The
Company's shares are traded through NASDAQ's Global Select Market,
symbol VIVO. Meridian's website address is www.meridianbioscience.com.
CONTACT: Meridian Bioscience, Inc.
Melissa Lueke, Vice President, CFO, 513-271-3700
Source: Meridian Bioscience, Inc.